Immunomodulatory Effect of Vitamin D in Colon Cancer Patients: a Randomized Clinical Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20171106001

Enrollment

Registered

2017-11-06

Start date

2017-11-20

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon cancer stage 1 and 2 Male or Female&#44

Interventions

Randomized block design by blocking on sex with two arms (vitamin D3 VS non&#45

vitamin D3 supplementations) will be used among 80 patients who meet inclusion and exclusion criteria. Patients in intervention group (40 patients) will receive daily 8&#44

000 IU of vitamin D3 supplementation for 3 months. Then&#44

the immunological response and vitamin D status will be observed.,Patients in conventional group (40 patients) will not receive daily 8&#44

000 IU of vitamin D3 supplementation for 3 months. They just receive standard treatment care as a conventional therapy. Then&#44

the immunological response and vitamin D status will be observed.

Experimental Dietary Supplement,No Intervention No treatment

Vitamin D receiver group,Conventional group

Eligibility

Sex/Gender

All

Age

30 Years to 75 Years

Inclusion criteria

Inclusion criteria: The participants have to meet the criteria as follow: (1) Colon cancer inpatients or outpatients stage I and II receiving treatment and care at the King Chulalongkorn Memorial Hospital and the Police General Hospital, upon signed informed consent (2) Male or Female, aged 30-75 years (3) Serum creatinine 3.5 mg/dl (7) WBC count > 5,000 cells/cu.mm (8) BMI 18.5-29.9 kg/m2 (9) Being at least 1 month after surgery (10) No previous chemotherapy or radiotherapy (11) Having Self-care ability or caregiver

Exclusion criteria

Exclusion criteria: The participants have not to meet the criteria as follow: (1) Regularly used of vitamin D-containing supplements > 800 IU/day, unless they discontinued vitamin D3 supplementation 2 months or more prior to enrollment (2) History of hypercalcemia or history of genitourinary stones (3) Serum calcium > 10.5 mg/dL (4) Use of medication interfering with vitamin D metabolism (5) Certain diseases i.e. HIV/AIDS, Diabetes mellitus, Thyroid, Renal and Liver disease (6) Pregnant women

Design outcomes

Primary

Measure	Time frame
Immunological markers 3 months Immunological and biochemical tests	—

Secondary

Measure	Time frame
vitamin D status 3 months biochemical test	—

Countries

Thailand

Contacts

Public ContactPanita Chaturawit

Nutrition and Dietetics Center, Theptarin Hospital

pchaturawit@gmail.com062-953-2456

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026